Cytori Therapeutics Inc (NASDAQ:CYTX) fell 2.3% on Wednesday . The stock traded as low as $0.40 and last traded at $0.43. 595,442 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 2,919,156 shares. The stock had previously closed at $0.44.

Several research firms recently weighed in on CYTX. B. Riley reiterated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research cut shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, Maxim Group set a $5.00 target price on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Friday, January 5th.

The stock has a market capitalization of $15.09, a P/E ratio of -0.48 and a beta of 3.21.

Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The firm had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $2.04 million. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. During the same quarter last year, the company earned ($0.26) earnings per share. equities analysts forecast that Cytori Therapeutics Inc will post -0.62 EPS for the current year.

In other Cytori Therapeutics news, major shareholder Bank Sa Swissquote sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the transaction, the insider now owns 5,496,655 shares in the company, valued at $2,088,728.90. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.90% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Perkins Capital Management Inc. lifted its stake in Cytori Therapeutics by 134.0% during the fourth quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock worth $644,000 after purchasing an additional 1,223,046 shares during the period. Sabby Management LLC lifted its stake in Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 355,504 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Cytori Therapeutics by 81.9% during the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after purchasing an additional 275,653 shares during the period. Hedge funds and other institutional investors own 7.34% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cytori Therapeutics (CYTX) Stock Price Down 2.3%” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.